<DOC>
	<DOC>NCT02972658</DOC>
	<brief_summary>This study is an extension of study I8D-MC-AZES (NCT02245737), the AMARANTH study. The purpose of this study is to evaluate the effectiveness of the study drug LY3314814 in participants with early Alzheimer's disease dementia at the time of entry into study I8D-MC-AZES.</brief_summary>
	<brief_title>A Study of LY3314814 in Early Alzheimer's Disease Dementia</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<criteria>Participants previously enrolled in AMARANTH (NCT02245737) who meet eligibility criteria for delayed start I8DMCAZFD. Participants who participate in AMARANTH (NCT02245737) who develop new conditions precluding them from enrolling into I8DMCAZFD.</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Alzheimer's Disease</keyword>
	<keyword>Dementia</keyword>
	<keyword>Brain Diseases</keyword>
	<keyword>Neurodegenerative Diseases</keyword>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Mental Disorders</keyword>
	<keyword>Delirium, Dementia, Amnestic, Cognitive Disorders</keyword>
	<keyword>Tauopathies</keyword>
	<keyword>Memory</keyword>
	<keyword>Amyloid</keyword>
</DOC>